Search

Your search keyword '"Klyasova, Galina"' showing total 47 results
Start Over Author "Klyasova, Galina"
47 results on '"Klyasova, Galina"'

1. The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study

Author

Soriano, Alex, Montravers, Philippe, Bassetti, Matteo, Klyasova, Galina, Daikos, George, Irani, Paurus, Stone, Gregory, Chambers, Richard, Peeters, Pascale, Shah, Mitesh, Hulin, Claire, Albuquerque, Natalia, Basin, Efim, Gaborit, Benjamin, Kourbeti, Irene, Menichetti, Francesco, Perez-Rodriguez, María Teresa, Pletz, Mathias W., Sanchez, Marisa, Trompa, Ivan, Verma, Anita, de Figueiredo, Maria Lavinea N., and Charbonneau, Claudie

Published
2023
Full Text
View/download PDF

4. The outcome of Ph-negative acute lymphoblastic leukemia presenting during pregnancy and treated on the Russian prospective multicenter trial RALL-2009

Author

Parovichnikova, Elena N., Troitskaya, Vera V., Gavrilina, Olga A., Sokolov, Andrey N., Kokhno, Alina V., Klyasova, Galina A., Kuzmina, Larisa A., Galstyan, Gennadiy M., Makhinya, Sergey A., Latyshkevich, Oleg A., Kaporskaya, Tatyana S., Lapin, Valery A., Chabaeva, Yulia A., Kulikov, Sergey M., and Savchenko, Valery G.

Published
2021
Full Text
View/download PDF

5. ABCL-070 Multicenter Randomized Controlled (Comparative) Open Prospective Study to Evaluate the Efficacy of the R-DA-EPOCH-21 and R-mNHL-BFM-90 ± Autologous Hematopoietic Stem Cell Transplantation Programs in Untreated Patients With de Novo Diffuse B-Cell Large Cell Lymphoma With Signs of Poor Prognosis - DLBCL-2015 Protocol

Author

Magomedova, Aminat, Kravchenko, Sergey, Misyurina, Anna, Mangasarova, Yana, Margolin, Oleg, Fastova, Ekaterina, Babaeva, Fatima, Gorenkova, Lilia, Bagova, Madina, Nesterova, Ekaterina, Sychevskaya, Ksenia, Moiseeva, Tatyana, Kovrigina, Alla, Obukhova, Tatyana, Dvirnyk, Valentina, Maryina, Salia, Gitis, Mikhail, Troitskaya, Vera, Galtseva, Irina, Galuzyak, Vladimir, Galstyan, Gennady, Spirin, Mikhail, Kostina, Irina, Sudarikov, Andrey, Nikulina, Elena, Biderman, Bella, Klyasova, Galina, Kulikov, Sergey, Chabaeva, Yulia, Zinina, Elena, Kryuchkova, Irina, Sizikova, Svetlana, Sergeyevicheva, Vera, Ksenzova, Tatyana, Anikina, Ekaterina, Shelekhova, Tatyana, Arzhanukhina, Olga, Kaplanov, Kamil, Konstantinova, Tatyana, Serdyuk, Olga, Sychyova, Tatyana, Chagorova, Tatyana, Nechunayeva, Irina, Anchukova, Lyudmila, Dzarasova, Oksana, Julhakyan, Hunan, Academician, Valery Savchenko, and Parovichnikova, Elena

Published
2022
Full Text
View/download PDF

6. Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients : Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group

Author

Averbuch, Diana, Tridello, Gloria, Hoek, Jennifer, Mikulska, Malgorzata, Akan, Hamdi, San Segundo, Lucrecia Yaňez, Pabst, Thomas, Özçelik, Tülay, Klyasova, Galina, Donnini, Irene, Wu, Depei, Gülbas, Zafer, Zuckerman, Tsila, de Sousa, Aida Botelho, Beguin, Yves, Xhaard, Aliénor, Bachy, Emmanuel, Ljungman, Per, de la Camara, Rafael, Rascon, Jelena, Camps, Isabel Ruiz, Vitek, Antonin, Patriarca, Francesca, Cudillo, Laura, Vrhovac, Radovan, Shaw, Peter J., Wolfs, Tom, O’Brien, Tracey, Avni, Batia, Silling, Gerda, Sabty, Firas Al, Graphakos, Stelios, Sankelo, Marja, Sengeloev, Henrik, Pillai, Srinivas, Matthes, Susanne, Melanthiou, Frederiki, Iacobelli, Simona, Styczynski, Jan, Engelhard, Dan, and Cesaro, Simone

Published
2017

9. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

Author

Marty, Francisco M, Ostrosky-Zeichner, Luis, Cornely, Oliver A, Mullane, Kathleen M, Perfect, John R, Thompson, George R, III, Alangaden, George J, Brown, Janice M, Fredricks, David N, Heinz, Werner J, Herbrecht, Raoul, Klimko, Nikolai, Klyasova, Galina, Maertens, Johan A, Melinkeri, Sameer R, Oren, Ilana, Pappas, Peter G, Ráčil, Zdeněk, Rahav, Galia, Santos, Rodrigo, Schwartz, Stefan, Vehreschild, J Janne, Young, Jo-Anne H, Chetchotisakd, Ploenchan, Jaruratanasirikul, Sutep, Kanj, Souha S, Engelhardt, Marc, Kaufhold, Achim, Ito, Masanori, Lee, Misun, Sasse, Carolyn, Maher, Rochelle M, Zeiher, Bernhardt, and Vehreschild, Maria J G T

Published
2016
Full Text
View/download PDF

12. ABCL-070 Multicenter Randomized Controlled (Comparative) Open Prospective Study to Evaluate the Efficacy of the R-DA-EPOCH-21 and R-mNHL-BFM-90 ± Autologous Hematopoietic Stem Cell Transplantation Programs in Untreated Patients With Diffuse B-Cell Large Cell Lymphoma With Signs of Poor Prognosis - DLBCL-2015 Protocol

Author

Magomedova, Aminat, primary, Kravchenko, Sergey, additional, Misyurina, Anna, additional, Mangasarova, Yana, additional, Margolin, Oleg, additional, Fastova, Ekaterina, additional, Babaeva, Fatima, additional, Gorenkova, Lilia, additional, Bagova, Madina, additional, Nesterova, Ekaterina, additional, Sychevskaya, Ksenia, additional, Moiseeva, Tatyana, additional, Kovrigina, Alla, additional, Obukhova, Tatyana, additional, Dvirnyk, Valentina, additional, Maryina, Salia, additional, Gitis, Mikhail, additional, Troitskaya, Vera, additional, Galtseva, Irina, additional, Galuzyak, Vladimir, additional, Galstyan, Gennady, additional, Spirin, Mikhail, additional, Kostina, Irina, additional, Sudarikov, Andrey, additional, Nikulina, Elena, additional, Biderman, Bella, additional, Klyasova, Galina, additional, Kulikov, Sergey, additional, Chabaeva, Yulia, additional, Zinina, Elena, additional, Kryuchkova, Irina, additional, Sizikova, Svetlana, additional, Sergeyevicheva, Vera, additional, Ksenzova, Tatyana, additional, Anikina, Ekaterina, additional, Shelekhova, Tatyana, additional, Arzhanukhina, Olga, additional, Kaplanov, Kamil, additional, Konstantinova, Tatyana, additional, Serdyuk, Olga, additional, Sychyova, Tatyana, additional, Chagorova, Tatyana, additional, Nechunayeva, Irina, additional, Anchukova, Lyudmila, additional, Dzarasova, Oksana, additional, Julhakyan, Hunan, additional, Academician, Valery Savchenko, additional, and Parovichnikova, Elena, additional

Published
2022
Full Text
View/download PDF

13. Poster: ABCL-070 Multicenter Randomized Controlled (Comparative) Open Prospective Study to Evaluate the Efficacy of the R-DA-EPOCH-21 and R-mNHL-BFM-90 ± Autologous Hematopoietic Stem Cell Transplantation Programs in Untreated Patients With de Novo Diffuse B-Cell Large Cell Lymphoma With Signs of Poor Prognosis - DLBCL-2015 Protocol

Author

Magomedova, Aminat, primary, Kravchenko, Sergey, additional, Misyurina, Anna, additional, Mangasarova, Yana, additional, Margolin, Oleg, additional, Fastova, Ekaterina, additional, Babaeva, Fatima, additional, Gorenkova, Lilia, additional, Bagova, Madina, additional, Nesterova, Ekaterina, additional, Sychevskaya, Ksenia, additional, Moiseeva, Tatyana, additional, Kovrigina, Alla, additional, Obukhova, Tatyana, additional, Dvirnyk, Valentina, additional, Maryina, Salia, additional, Gitis, Mikhail, additional, Troitskaya, Vera, additional, Galtseva, Irina, additional, Galuzyak, Vladimir, additional, Galstyan, Gennady, additional, Spirin, Mikhail, additional, Kostina, Irina, additional, Sudarikov, Andrey, additional, Nikulina, Elena, additional, Biderman, Bella, additional, Klyasova, Galina, additional, Kulikov, Sergey, additional, Chabaeva, Yulia, additional, Zinina, Elena, additional, Kryuchkova, Irina, additional, Sizikova, Svetlana, additional, Sergeyevicheva, Vera, additional, Ksenzova, Tatyana, additional, Anikina, Ekaterina, additional, Shelekhova, Tatyana, additional, Arzhanukhina, Olga, additional, Kaplanov, Kamil, additional, Konstantinova, Tatyana, additional, Serdyuk, Olga, additional, Sychyova, Tatyana, additional, Chagorova, Tatyana, additional, Nechunayeva, Irina, additional, Anchukova, Lyudmila, additional, Dzarasova, Oksana, additional, Julhakyan, Hunan, additional, Academician, Valery Savchenko, additional, and Parovichnikova, Elena, additional

Published
2022
Full Text
View/download PDF

16. Recurrent bloodstream infections after allogeneic hematopoietic cell transplantation.

Author

Akhmedov, Mobil, Klyasova, Galina, Kuzmina, Larisa, and Parovichnikova, Elena

Abstract

Although colonization is an established risk factor for bloodstream infection (BSI) due to identical strain, prior infection with resistant bacteria should also be considered during the management of febrile neutropenia. This study aimed to analyze the rate and etiology of recurrent BSI in allogeneic hematopoietic cell transplant (allo-HCT) recipients to determine its potential impact on decision-making. The retrospective study included 284 allo-HCT recipients. Recurrent BSI was defined as a new BSI episode occurring in a period of more than 72 hours after antibiotic withdrawal. Overall, 104 patients (36.6%) developed at least one BSI, and 23 of them (22.1%) experienced recurrent BSI episodes (n = 30). Median time to recurrent BSI was 41 days (range 5–526 days). Recurrent BSI was associated with second allo-HCT (p < 0.0001), primary (p = 0.021), and secondary graft failure (p = 0.024). Carbapenem-resistant gram-negative bacteria were more common during recurrent BSI episodes (23.7% vs. 6.0%; p = 0.003). In only 17.5% patients experiencing recurrent BSI episode and in only 3.9% of patients with at least one BSI episode phenotypically identical recurring pathogen was isolated. In view of low rate of recurrent BSI due to identical pathogen, empirical antimicrobial therapy should not be based on data on previous BSI episodes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)

Author

Salmanton-García, Jon, Seidel, Danila, Koehler, Philipp, Mellinghoff, Sibylle, Herbrecht, Raoul, Klimko, Nikolai, Ráčil, Zdeněk, Falces-Romero, Iker, Ingram, Paul, Benítez-Peñuela, Miguel-Ángel, Rodríguez, José Yesid, Desoubeaux, Guillaume, Barać, Aleksandra, García-Vidal, Carolina, Hoenigl, Martin, Mehta, Sanjay, Cheng, Matthew, Klyasova, Galina, Heinz, Werner, Iqbal, Nousheen, Krause, Robert, Ostermann, Helmut, Penack, Olaf, Schalk, Enrico, Sheppard, Donald, Willinger, Birgit, Wisplinghoff, Hilmar, Vehreschild, J Janne, Cornely, Oliver, Vehreschild, Maria, Khedr, Reham Abdelaziz, Arencibia-Núñez, Alberto, Avilés-Robles, Martha, Banke, Ingo, Basher, Ariful, Benachinamardi, Keertilaxmi, Bertz, Harmut, Chakrabarti, Arunaloke, Drgona, Lubos, García-Martínez, Jesús, García-Rodríguez, Julio, Gräber, Sandra, Härter, Georg, Klein, Michael, Kouba, Michal, Lee, Dong-Gun, Le Govic, Yohann, Leo, Fabian, Maertens, Johan, Maschmeyer, Georg, Meintker, Lisa, Mo, Xiao-Dong, Müller, Lena-Katharina, Müller, Nicolas, Nel, Jeremy Stephen, Novák, Jan, Patel, Atul, Pfäfflin, Frieder, Pozo-Laderas, Juan-Carlos, Puerta-Alcalde, Pedro, Rodríguez-Guardado, Azucena, Schroers, Roland, Shekar, Vandana, Shenoi, Susan, Silling, Gerda, Vinh, Donald, Waizel-Haiat, Salomón, Yee Yee, Mandy Yap, Prakash, Peralam Yegneswaran, Žák, Pavel, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Service d'Hématologie, CHU Strasbourg, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Medicine, Medical University Graz, Schwerpunkt Infektiologie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Department of Haematology and Oncology, Medical Clinic III, University Hospital Munich—Großhadern, Ludwig Maximilian University, Klinik für Hämatologie und Onkologie, Charité, Campus Benjamin Franklin, Department of Haematology/Oncology, Magdeburg University Hospital, McGill University = Université McGill [Montréal, Canada], Medizinische Universität Wien = Medical University of Vienna, University Hospital of Cologne [Cologne], Postgraduate Institute of Medical Education and Research, Laboratoire de psychologie cognitive (LPC), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Anofel Cryptosporidium National Network, Department of Hematology, University Hospital Gasthuisberg, Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Real Expression Artificial Life (IRIT-REVA), Institut de recherche en informatique de Toulouse (IRIT), Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées, Medizinische Klinik A des Universitätsklinikums Münster, Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), University Hospital Gasthuisberg [Leuven], Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, 0301 basic medicine, Posaconazole, Antifungal Agents, [SDV]Life Sciences [q-bio], Gastroenterology, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Amphotericin B, Pharmacology (medical), Prospective Studies, Registries, 030212 general & internal medicine, Child, Prospective cohort study, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, ComputingMilieux_MISCELLANEOUS, Antiinfective agent, Standard treatment, Middle Aged, 3. Good health, Infectious Diseases, Tolerability, Child, Preschool, Mucorales, Female, medicine.drug, Adult, Microbiology (medical), medicine.medical_specialty, Adolescent, Drug Compounding, Matched-Pair Analysis, 030106 microbiology, Young Adult, 03 medical and health sciences, Pharmacokinetics, Internal medicine, parasitic diseases, medicine, Humans, Mucormycosis, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, [INFO]Computer Science [cs], Aged, Pharmacology, business.industry, Infant, Newborn, Infant, Triazoles, medicine.disease, business, MESH: amphotericin b, antifungal agents, cancer, kidney failure, mucormycosis, surgical procedures, operative, suspensions, mortality, posaconazole, Invasive Fungal Infections
Abstract

Background First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension. With the approval of posaconazole new formulations, patients could benefit from improved pharmacokinetics, safety and tolerability. Objectives Our aim was to assess the effectiveness of posaconazole new formulations for IM treatment. Methods We performed a case-matched analysis with proven or probable IM patients from the FungiScope® Registry. First-line posaconazole new formulations (1st-POSnew) and first-line amphotericin B plus posaconazole new formulations (1st-AMB+POSnew) cases were matched with first-line amphotericin B-based (1st-AMB) treatment controls. Salvage posaconazole new formulations (SAL-POSnew) cases were matched with salvage posaconazole oral suspension (SAL-POSsusp) controls. Each case was matched with up to three controls (based on severity, haematological/oncological malignancy, surgery and/or renal dysfunction). Results Five patients receiving 1st-POSnew, 18 receiving 1st-AMB+POSnew and 22 receiving SAL-POSnew were identified. By day 42, a favourable response was reported for 80.0% (n = 4/5) of patients receiving 1st-POSnew, for 27.8% (n = 5/18) receiving 1st-AMB+POSnew and for 50.0% (n = 11/22) receiving SAL-POSnew. Day 42 all-cause mortality of patients receiving posaconazole new formulations was lower compared with controls [20.0% (n = 1/5) in 1st-POSnew versus 53.3% (n = 8/15) in 1st-AMB; 33.3% (n = 6/18) in 1st-AMB+POSnew versus 52.0% (n = 26/50) in 1st-AMB; and 0.0% (n = 0/22) in SAL-POSnew versus 4.4% (n = 2/45) in SAL-POSsusp]. Conclusions Posaconazole new formulations were effective in terms of treatment response and associated mortality of IM. While posaconazole new formulations may be an alternative for treatment of IM, the limited sample size of our study calls for a cautious interpretation of these observations.

Published
2019

18. Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope (R)-Global Registry for Emerging Fungal Infections

Author

Salmanton-Garcia, Jon, Koehler, Philipp, Kindo, Anupma, Falces-Romero, Iker, Garcia-Rodriguez, Julio, Racil, Zdenek, Chen, Sharon C-A, Klimko, Nikolai, Desoubeaux, Guillaume, Thompson, George R., III, Benitez-Penuela, Miguel-Angel, Rodriguez, Jose-Yesid, Sheppard, Donald C., Hoenigl, Martin, Le Govic, Yohann, Badali, Hamid, Baddley, John W., Chander, Jagdish, Ingram, Paul R., Pakstis, Diana L., Mellinghoff, Sibylle C., Atici, Serkan, Cesaro, Simone, Chakrabarti, Arunaloke, Dupont, Damien, Gonzalez, Gloria M., Hatvani, Lorant, Herbrecht, Raoul, Klyasova, Galina, Lass-Florl, Cornelia, Mares, Mihai, Mullane, Kathleen, Vinh, Donald C., Wisplinghoff, Hilmar, Lackner, Michaela, Cornely, Oliver A., Seidel, Danila, Salmanton-Garcia, Jon, Koehler, Philipp, Kindo, Anupma, Falces-Romero, Iker, Garcia-Rodriguez, Julio, Racil, Zdenek, Chen, Sharon C-A, Klimko, Nikolai, Desoubeaux, Guillaume, Thompson, George R., III, Benitez-Penuela, Miguel-Angel, Rodriguez, Jose-Yesid, Sheppard, Donald C., Hoenigl, Martin, Le Govic, Yohann, Badali, Hamid, Baddley, John W., Chander, Jagdish, Ingram, Paul R., Pakstis, Diana L., Mellinghoff, Sibylle C., Atici, Serkan, Cesaro, Simone, Chakrabarti, Arunaloke, Dupont, Damien, Gonzalez, Gloria M., Hatvani, Lorant, Herbrecht, Raoul, Klyasova, Galina, Lass-Florl, Cornelia, Mares, Mihai, Mullane, Kathleen, Vinh, Donald C., Wisplinghoff, Hilmar, Lackner, Michaela, Cornely, Oliver A., and Seidel, Danila

Abstract

Objectives: Emerging invasive fungal infections (IFI) have become a notable challenge. Apart from the more frequently described fusariosis, lomentosporiosis, mucormycosis, scedosporiosis, and certain dematiaceae or yeasts, little is known about extremely rare IFI. Methods: Extremely rare IFI collected in the FungiScope (R) registry were grouped as Dematiaceae, Hypocreales, Saccharomycetales, Eurotiales, Dermatomycetes, Agaricales, and Mucorales. Results: Between 2003 and June 2019, 186 extremely rare IFI were documented in FungiScope (R). Dematiaceae (35.5%), Hypocreales (23.1%), Mucorales (11.8%), and Saccharomycetales (11.3%) caused most IFI. Most patients had an underlying malignancy (38.7%) with acute leukemia accounting for 50% of cancers. Dissemination was observed in 26.9% of the patients. Complete or partial clinical response rate was 68.3%, being highest in Eurotiales (82.4%) and in Agaricales (80.0%). Overall mortality rate was 29.3%, ranging from 11.8% in Eurotiales to 50.0% in Mucorales. Conclusions: Physicians are confronted with a complex variety of fungal pathogens, for which treatment recommendations are lacking and successful outcome might be incidental. Through an international consortium of physicians and scientists, these cases of extremely rare IFI can be collected to further investigate their epidemiology and eventually identify effective treatment regimens. (C) 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Published
2020

20. Intercontinental study on pre-engraftment and post-engraftment Gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: Risk factors and association with mortality

Author

Averbuch, Diana, primary, Tridello, Gloria, additional, Hoek, Jennifer, additional, Mikulska, Malgorzata, additional, Pabst, Thomas, additional, Yaňez San Segundo, Lucrecia, additional, Akan, Hamdi, additional, Özçelik, Tülay, additional, Donnini, Irene, additional, Klyasova, Galina, additional, Botelho de Sousa, Aida, additional, Zuckerman, Tsila, additional, Tecchio, Cristina, additional, de la Camara, Rafael, additional, Aki, Sahika Zeynep, additional, Ljungman, Per, additional, Gülbas, Zafer, additional, Nicolas-Virelizier, Emmanuelle, additional, Calore, Elisabetta, additional, Perruccio, Katia, additional, Ram, Ron, additional, Annaloro, Claudio, additional, Martino, Rodrigo, additional, Avni, Batia, additional, Shaw, Peter J., additional, Jungova, Alexandra, additional, Codeluppi, Katia, additional, O'Brien, Tracey, additional, Waszczuk-Gajda, Anna, additional, Batlle, Montserrat, additional, Pouli, Anastasia, additional, Lueck, Catherina, additional, Gil, Lidia, additional, Iacobelli, Simona, additional, Styczynski, Jan, additional, Engelhard, Dan, additional, and Cesaro, Simone, additional

Published
2020
Full Text
View/download PDF

22. Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScopeⓇ—Global Registry for Emerging Fungal Infections

Author

Salmanton-García, Jon, primary, Koehler, Philipp, additional, Kindo, Anupma, additional, Falces-Romero, Iker, additional, García-Rodríguez, Julio, additional, Ráčil, Zdeněk, additional, Chen, Sharon C.-A., additional, Klimko, Nikolai, additional, Desoubeaux, Guillaume, additional, Thompson, George R., additional, Benítez-Peñuela, Miguel-Ángel, additional, Rodríguez, José-Yesid, additional, Sheppard, Donald C., additional, Hoenigl, Martin, additional, Le Govic, Yohann, additional, Badali, Hamid, additional, Baddley, John W., additional, Chander, Jagdish, additional, Ingram, Paul R., additional, Pakstis, Diana L., additional, Mellinghoff, Sibylle C., additional, Atıcı, Serkan, additional, Cesaro, Simone, additional, Chakrabarti, Arunaloke, additional, Dupont, Damien, additional, González, Gloria M., additional, Hatvani, Lóránt, additional, Herbrecht, Raoul, additional, Klyasova, Galina, additional, Lass-Flörl, Cornelia, additional, Mareș, Mihai, additional, Mullane, Kathleen, additional, Vinh, Donald C., additional, Wisplinghoff, Hilmar, additional, Lackner, Michaela, additional, Cornely, Oliver A., additional, Seidel, Danila, additional, Alexander, Barbara D., additional, Almagro-Molto, María, additional, Álvarez-Duarte, Eduardo, additional, Avilés-Robles, Martha, additional, Barać, Aleksandra, additional, Chrenková, Vanda, additional, Cornejo-Juárez, Patricia, additional, Desbois-Nogard, Nicole, additional, Fernández-Ruiz, Mario, additional, Figueira, Luis, additional, García-Martínez, Jesús, additional, Gräber, Sandra, additional, Graf, Barbara, additional, Haerter, Georg, additional, Haider, Shariq, additional, Hartman, Pamela, additional, Heinemann, Melina, additional, Ikram, Aamer, additional, Janvier, Frédéric, additional, Jenks, Jeffrey D., additional, Kauffman, Carol, additional, Krause, Robert, additional, Luong, Me-Linh, additional, Malik, Shruti, additional, Marconi, Vincent, additional, Martino, Rodrigo, additional, Mehta, Sanjay R., additional, Meintker, Lisa, additional, Mocná, Andrea, additional, Morris, Michele I., additional, Pasqualotto, Alessandro C., additional, Patel, Atul, additional, Penack, Olaf, additional, Pichon, Nicolas, additional, Pletz, Mathias W., additional, Seas, Carlos, additional, Sili, Uluhan, additional, Slavin, Monica, additional, Uno, Kenji, additional, Vazquez, Jose A., additional, Weber, Thomas, additional, Weinbergerova, Barbora, additional, Yilmaz-Karapinar, Deniz, additional, Yilmaz-Semerci, Seda, additional, and Yu, Jin, additional

Published
2020
Full Text
View/download PDF

23. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients

Author

Cesaro, Simone, Dalianis, Tina, Rinaldo, Christine Hanssen, Koskenvuo, Minna, Pegoraro, Anna, Einsele, Hermann, Cordonnier, Catherine, Hirsch, Hans H., Akova, Murat, Aljurf, Mahmoud, Averbuch, Dina, Barnes, Rosemary, Blennow, Ola, Bochud, Pierre-Yves, Bouza, Emilio, Bretagne, Stephane, Brüggemann, Roger, Calandra, Thierry, Carratala, Jordi, Cornely, Oliver, de la Camara, Rafael, Donnelly, Peter, Drgona, Lubos, Duarte, Rafael, Engelhard, Dan, Fox, Christopher, Girmenia, Corrado, Groll, Andreas, Heldal, Dag, Helweg-Larsen, Jannick, Herbrecht, Raoul, Johnson, Elisabeth, Klyasova, Galina, Lagrou, Katrien, Lewis, Russell E., Ljungman, Per, Maertens, Johan, Mikulska, Malgorzata, Nucci, Marcio, Padoin, Christophe, Pagano, Livio, Pagliuca, Antonio, Racil, Zdenek, Ribaud, Patricia, Rizzi-Puechal, Valérie, Roilides, Emmanuel, Robin, Christine, Rovira, Montserrat, Rupp, Markus, Sanchez, Sonia, Schellongowski, Peter, Sedlacek, Peter, Sinko, Janos, Slavin, Monica, Ferreira, Isabella Sousa, Styczynski, Jan, Tissot, Frederic, Viscoli, Claudio, Ward, Katherine, Witschi, Anne-Therese, Cesaro, Simone, Dalianis, Tina, Rinaldo, Christine Hanssen, Koskenvuo, Minna, Pegoraro, Anna, Einsele, Hermann, Cordonnier, Catherine, Hirsch, Hans H., Akova, Murat, Aljurf, Mahmoud, Averbuch, Dina, Barnes, Rosemary, Blennow, Ola, Bochud, Pierre-Yve, Bouza, Emilio, Bretagne, Stephane, Brüggemann, Roger, Calandra, Thierry, Carratala, Jordi, Cornely, Oliver, de la Camara, Rafael, Donnelly, Peter, Drgona, Lubo, Duarte, Rafael, Engelhard, Dan, Fox, Christopher, Girmenia, Corrado, Groll, Andrea, Heldal, Dag, Helweg-Larsen, Jannick, Herbrecht, Raoul, Johnson, Elisabeth, Klyasova, Galina, Lagrou, Katrien, Lewis, Russell E., Ljungman, Per, Maertens, Johan, Mikulska, Malgorzata, Nucci, Marcio, Padoin, Christophe, Pagano, Livio, Pagliuca, Antonio, Racil, Zdenek, Ribaud, Patricia, Rizzi-Puechal, Valérie, Roilides, Emmanuel, Robin, Christine, Rovira, Montserrat, Rupp, Marku, Sanchez, Sonia, Schellongowski, Peter, Sedlacek, Peter, Sinko, Jano, Slavin, Monica, Ferreira, Isabella Sousa, Styczynski, Jan, Tissot, Frederic, Viscoli, Claudio, Ward, Katherine, and Witschi, Anne-Therese

Subjects
Cystiti, Drug resistance, medicine.disease_cause, law.invention, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, Risk Factors, law, Cystitis, Pharmacology (medical), guidelines, Hematopoietic Stem Cell Transplantation, BK virus, Infectious Diseases, 030220 oncology & carcinogenesis, Hemorrhagic cystitis, BK virus, stem cell transplantation, guidelines, Human, Cidofovir, Microbiology (medical), medicine.medical_specialty, Urinary Bladder, Viremia, stem cell transplantation, Polyomavirus Infection, 03 medical and health sciences, Antibiotic resistance, Internal medicine, Drug Resistance, Viral, Hemorrhagic cystitis, medicine, Humans, Pharmacology, Polyomavirus Infections, business.industry, Risk Factor, Tumor Virus Infection, Pharmacology, Pharmacology (medical), Infectious Diseases, medicine.disease, BK Viru, Clinical trial, Tumor Virus Infections, Settore MED/15 - MALATTIE DEL SANGUE, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], chemistry, business, 030215 immunology
Abstract

Contains fulltext : 190548.pdf (Publisher’s version ) (Closed access) Objectives: To define guidelines for BK polyomavirus (BKPyV)-associated haemorrhagic cystitis (BKPyV-HC) after paediatric and adult HSCT. Methods: Review of English literature and evidence-based recommendations by expert consensus. Results: BKPyV-HC occurs in 8%-25% of paediatric and 7%-54% of adult recipients undergoing allogeneic HSCT. Diagnosis requires the triad of cystitis, macro-haematuria and high urine BKPyV loads >7 log10 copies/mL, and exclusion of other relevant aetiologies. BKPyV viraemia is frequent and may serve as a more specific semiquantitative follow-up marker. No randomized controlled trials are available to inform antiviral prophylaxis or treatment. However, hyper-hydration and/or bladder irrigation showed limited prophylactic value. Fluoroquinolones are not effective for prophylaxis or treatment, but rather increase antibiotic resistance. Hyperbaric oxygen or fibrin glue is marginally effective based on small case series from correspondingly equipped centres. Although cidofovir has been reported to improve and/or reduce BKPyV viraemia or viruria, the current data do not support its regular use. Conclusions: BKPyV-HC remains a disabling unmet clinical need in HSCT that requires novel approaches supported by proper clinical trials.

Published
2018

24. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients

Author

Cordonnier, Catherine, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Peter Donnelly, J., Alanio, Alexandre, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stephane, Maertens, Johan, Agrawal, Samir, Kibbler, Christopher, Pagliuca, Antonio, Ward, Katherine, Akova, Murat, Herbrecht, Raoul, Mallet, Vincent, Ribaud, Patricia, Aljurf, Mahmoud, Averbuch, Dina, Engelhard, Dan, Berg, Thomas, Cornely, Oliver, Penack, Olaf, van Boemmel, Florian, von Lilienfeld-Toal, Marie, Blennow, Ola, Ljungman, Per, Bruggemann, Roger, Donnelly, Peter, Kullberg, Bart-Jan, Melchers, Willem, Calandra, Thierry, Hirsch, Hans, Marchetti, Oscar, Orasch, Christina, Tissot, Frederic, Castagnola, Elio, Girmenia, Corrado, Mikulska, Malgorzata, Pagano, Livio, Viscoli, Claudio, De La Camara, Rafael, Duarte, Rafael, Munoz, Patricia, Drgona, Lubos, Hargreaves, Ruth, Hubacek, Petr, Kouba, Michal, Racil, Zdenek, Klyasova, Galina, Pettrikos, George, Roilides, Emmanuel, Skiada, Anna, Rizzi-Puechal, Valã©rie, Sinko, Janos, Slavin, Monica, Styczynski, Jan, Tweddle, Lorraine, Wood, Craig, Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Department of Haematology, Oncoematologia Pediatrica, Policlinico G. B. Rossi, Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Radboud university [Nijmegen], Université Sorbonne Paris Cité (USPC), Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Lausanne University Hospital, Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Department of Hematology, University Hospital Gasthuisberg, The ECIL-5 meeting was supported by unrestricted educational grants from Astellas Pharma, Gilead Sciences, Merck, and Pfizer. The ECIL-6 meeting was supported by unrestricted educational grants from Basilea, Gilead Sciences, Merck, and Pfizer, on behalf of the Fifth European Conference on Infections in Leukemia (ECIL-5†), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and The European Leukemia Net (ELN) (61 collabrators), Radboud University [Nijmegen], University Hospital Gasthuisberg [Leuven], Julius-Maximilians-Universität Würzburg (JMU), and Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Antifungal Agents, [SDV]Life Sciences [q-bio], medicine.medical_treatment, 030106 microbiology, Disease, Hematopoietic stem cell transplantation, Pneumocystis carinii, Chemoprevention, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Immunocompromised Host, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Pneumocystis jirovecii, Pharmacology (medical), Intensive care medicine, Hematologic Neoplasms, Pneumonia, Pneumocystis, Stem Cell Transplantation, Transplant Recipients, Pharmacology, Infectious Diseases, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], Hematology, biology, Pneumocystis, business.industry, Mortality rate, Pneumonia, biology.organism_classification, medicine.disease, Penumocytis pneumonia, 3. Good health, Leukemia, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], 030220 oncology & carcinogenesis, immunocomrpomised host, Pnemocystis jirovecii, Stem cell, immunocomrpomised host, Penumocytis pneumonia, Pnemocystis jirovecii, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Abstract

Contains fulltext : 171209.pdf (Publisher’s version ) (Closed access) Pneumocystis jirovecii can cause life-threatening pneumonia following treatment for haematological malignancies or after HSCT. The mortality rate of P. jirovecii pneumonia (PCP) in these patients is 30%-60%, especially after HSCT. The clinical presentation of PCP in haematology differs from that associated with HIV infection, with the disease being acute and more often severe, having a lower fungal burden and being more frequently linked to treatment with corticosteroids. Most cases occur in patients not receiving adequate prophylaxis. The development of new therapies, including targeted treatments and monoclonal antibodies in various haematological diseases, justifies constant vigilance in order to identify new at-risk populations and give prophylaxis accordingly. The fifth and sixth European Conferences on Infections in Leukaemia (ECIL-5 and ECIL-6) aimed to review risk factors for PCP in haematology patients and to establish evidence-based recommendations for PCP diagnosis, prophylaxis and treatment. This article focuses on the magnitude of the problem, the main differences in clinical presentation between haematology patients and other immunocompromised populations, especially HIV-infected patients, and the main risk factors.

Published
2016

25. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines

Author

Mikulska, Malgorzata, Averbuch, Diana, Tissot, Frederic, Cordonnier, Catherine, Akova, Murat, Calandra, Thierry, Ceppi, Marcello, Bruzzi, Paolo, Viscoli, Claudio, Aljurf, Mahmoud, Averbuch, Dina, Barnes, Rosemary, Blennow, Ola, Bochud, Pierre-Yve, Bouza, Emilio, Bretagne, Stephane, Brã1⁄4ggemann, Roger, Carratala, Jordi, Cesaro, Simone, Cornely, Oliver, Dalianis, Tina, De La Camara, Rafael, Donnelly, Peter, Drgona, Lubo, Duarte, Rafael, Einsele, Hermann, Engelhard, Dan, Fox, Christopher, Girmenia, Corrado, Groll, Andrea, Heldal, Dag, Larsen, Jannick Helweg, Herbrecht, Raoul, Hirsch, Han, Johnson, Elisabeth, Klyasova, Galina, Koskuenvo, Minna, Lagrou, Katrien, Lewis, Russel E., Ljungman, Per, Maertens, Johan, Maschmeyer, Georg, Nucci, Marcio, Padoin, Christophe, Pagano, Livio, Pagliuca, Antonio, Racil, Zdenek, Ribaud, Patricia, Rinaldo, Christine, Puechal, Valérie Rizzi, Roilides, Emmanuel, Robin, Christine, Rovira, Montserrat, Rupp, Marku, Sanchez, Sonia, Schellongowski, Peter, Sedlacek, Peter, Sinko, Jano, Slavin, Monica, Ferreira, Isabella Sousa, Styczynski, Jan, Ward, Katherine, Witschi, Anne-Therese, Pagano, Livio (ORCID:0000-0001-8287-928X), Mikulska, Malgorzata, Averbuch, Diana, Tissot, Frederic, Cordonnier, Catherine, Akova, Murat, Calandra, Thierry, Ceppi, Marcello, Bruzzi, Paolo, Viscoli, Claudio, Aljurf, Mahmoud, Averbuch, Dina, Barnes, Rosemary, Blennow, Ola, Bochud, Pierre-Yve, Bouza, Emilio, Bretagne, Stephane, Brã1⁄4ggemann, Roger, Carratala, Jordi, Cesaro, Simone, Cornely, Oliver, Dalianis, Tina, De La Camara, Rafael, Donnelly, Peter, Drgona, Lubo, Duarte, Rafael, Einsele, Hermann, Engelhard, Dan, Fox, Christopher, Girmenia, Corrado, Groll, Andrea, Heldal, Dag, Larsen, Jannick Helweg, Herbrecht, Raoul, Hirsch, Han, Johnson, Elisabeth, Klyasova, Galina, Koskuenvo, Minna, Lagrou, Katrien, Lewis, Russel E., Ljungman, Per, Maertens, Johan, Maschmeyer, Georg, Nucci, Marcio, Padoin, Christophe, Pagano, Livio, Pagliuca, Antonio, Racil, Zdenek, Ribaud, Patricia, Rinaldo, Christine, Puechal, Valérie Rizzi, Roilides, Emmanuel, Robin, Christine, Rovira, Montserrat, Rupp, Marku, Sanchez, Sonia, Schellongowski, Peter, Sedlacek, Peter, Sinko, Jano, Slavin, Monica, Ferreira, Isabella Sousa, Styczynski, Jan, Ward, Katherine, Witschi, Anne-Therese, and Pagano, Livio (ORCID:0000-0001-8287-928X)

Abstract

Objectives Fluoroquinolone (FQ) prophylaxis was recommended in 2005 by European Conference on Infections in Leukemia (ECIL) for patients with prolonged neutropenia. In consideration of a worldwide increase in antibiotic resistance, the issue of FQ prophylaxis during neutropenia was re-evaluated. Methods Literature review of randomised controlled trials (RCT) and observational studies published in years 2006–2014 was performed. Their results were analysed in meta-analysis. Meta-regression model was applied to evaluate whether the rates of FQ resistance in community and hospital settings influenced the efficacy of FQ prophylaxis. The impact of FQ prophylaxis on colonisation and infection with resistant bacteria was reviewed. Results Two RCTs and 12 observational studies were identified. FQ prophylaxis did not have effect on mortality (pooled OR 1.01, 95%CI 0.73–1.41), but was associated with lower rate of bloodstream infections (BSI) (pooled OR 0.57, 95%CI 0.43–0.74) and episodes of fever during neutropenia (pooled OR 0.32, 95%CI 0.20–0.50). No effect of the background rate of FQ resistance on the efficacy of FQ prophylaxis was observed. In few studies, FQ prophylaxis resulted in an increased colonisation or infection with FQ- or multi-drug resistant strains. Conclusions The possible benefits of FQ prophylaxis on BSI rate, but not on overall mortality, should be weighed against its impact in terms of toxicity and changes in local ecology in single centres.

Published
2018

26. still a concern in patients with haematological malignancies and stem cell transplant recipients-authors' response

Author

Cordonnier, Catherine, Alanio, Alexandre, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J.G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stephane, Maertens, Johan, Agrawal, Samir, Akova, Murat, Aljurf, Mahmoud, Averbuch, Dina, Berg, Thomas, Blennow, Ola, Bruggemann, Roger, Calandra, Thierry, Castagnola, Elio, Cornely, Oliver, De La Camara, Rafael, Drgona, Lubos, Duarte, Rafael, Engelhard, Dan, Girmenia, Corrado, Hargreaves, Ruth, Herbrecht, Raoul, Hirsch, Hans, Hubacek, Petr, Kibbler, Christopher, Klyasova, Galina, Kouba, Michal, Kullberg, Bart Jan, Ljungman, Per, Mallet, Vincent, Marchetti, Oscar, Mikulska, Malgorzata, Munoz, Patricia, Orasch, Christina, Pagano, Livio, Pagliuca, Antonio, Penack, Olaf, Pettrikos, George, Racil, Zdenek, Ribaud, Patricia, Rizzi-Puechal, Valerie, Roilides, Emmanuel, on behalf of the Fifth European Conference on Infections in Leukemia (ECIL-5), The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN), Instituto de Higiene e Medicina Tropical (IHMT), Global Health and Tropical Medicine (GHTM), and TB, HIV and opportunistic diseases and pathogens (THOP)

Subjects
Carinii-pneumonia, Aids, Infectious Diseases, ECIL guidelines, SDG 3 - Good Health and Well-being, Outbreaks, Infection, Infants, Management
Abstract

Made available in DSpace on 2021-09-24T00:56:32Z (GMT). No. of bitstreams: 0 Previous issue date: 2017-04-01 publishersversion published

Published
2017

27. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients-authors' response

Author

Cordonnier, Catherine, Alanio, Alexandre, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stéphane, Maertens, Johan, Agrawal, Samir, Akova, Murat, Aljurf, Mahmoud, Averbuch, Dina, Berg, Thomas, Blennow, Ola, Brüggemann, Roger, Calandra, Thierry, Castagnola, Elio, Cornely, Oliver, De La Camara, Rafael, Drgona, Lubos, Duarte, Rafael, Engelhard, Dan, Girmenia, Corrado, Hargreaves, Ruth, Herbrecht, Raoul, Hirsch, Hans, Hubacek, Petr, Kibbler, Christopher, Klyasova, Galina, Kouba, Michal, Kullberg, Bart-Jan, Ljungman, Per, Mallet, Vincent, Marchetti, Oscar, Mikulska, Malgorzata, Munoz, Patricia, Orasch, Christina, Pagano, Livio, Pagliuca, Antonio, Penack, Olaf, Pettrikos, George, Racil, Zdenek, Ribaud, Patricia, Rizzi-Puechal, Valérie, Roilides, Emmanuel, Sinko, Janos, Skiada, Anna, Slavin, Monica, Styczynski, Jan, Tissot, Frederic, Tweddle, Lorraine, van Boemmel, Florian, von Lilienfeld-Toal, Marie, Viscoli, Claudio, Ward, Katherine, and Wood, Craig

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, 030106 microbiology, HIV Infections, Pneumocystis carinii, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), Hematologic Neoplasms, Humans, Pneumonia, Pneumocystis, Stem Cell Transplantation, Pharmacology, Pharmacology (medical), Infectious Diseases, Medicine, In patient, Intensive care medicine, hematopoietic stem cell transplant, business.industry, Pneumocystis, PNEUMOCYSTIS JIROVECI, Pneumocystis jiroveci, infection, hematopoietic stem cell transplant, Pneumocystis jirovecii Pneumonia, Pneumocystis jiroveci, Pneumonia, medicine.disease, infection, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Stem cell, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Abstract

Contains fulltext : 169784.pdf (Publisher’s version ) (Closed access)

Published
2017

28. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines

Author

Mikulska, Malgorzata, primary, Averbuch, Diana, additional, Tissot, Frederic, additional, Cordonnier, Catherine, additional, Akova, Murat, additional, Calandra, Thierry, additional, Ceppi, Marcello, additional, Bruzzi, Paolo, additional, Viscoli, Claudio, additional, Aljurf, Mahmoud, additional, Averbuch, Dina, additional, Barnes, Rosemary, additional, Blennow, Ola, additional, Bochud, Pierre-Yves, additional, Bouza, Emilio, additional, Bretagne, Stephane, additional, Brüggemann, Roger, additional, Carratala, Jordi, additional, Cesaro, Simone, additional, Cornely, Oliver, additional, Dalianis, Tina, additional, De La Camara, Rafael, additional, Donnelly, Peter, additional, Drgona, Lubos, additional, Duarte, Rafael, additional, Einsele, Hermann, additional, Engelhard, Dan, additional, Fox, Christopher, additional, Girmenia, Corrado, additional, Groll, Andreas, additional, Heldal, Dag, additional, Larsen, Jannick Helweg, additional, Herbrecht, Raoul, additional, Hirsch, Hans, additional, Johnson, Elisabeth, additional, Klyasova, Galina, additional, Koskuenvo, Minna, additional, Lagrou, Katrien, additional, Lewis, Russel E., additional, Ljungman, Per, additional, Maertens, Johan, additional, Maschmeyer, Georg, additional, Mikulska, Malgorzata, additional, Nucci, Marcio, additional, Padoin, Christophe, additional, Pagano, Livio, additional, Pagliuca, Antonio, additional, Racil, Zdenek, additional, Ribaud, Patricia, additional, Rinaldo, Christine, additional, Puechal, Valérie Rizzi, additional, Roilides, Emmanuel, additional, Robin, Christine, additional, Rovira, Montserrat, additional, Rupp, Markus, additional, Sanchez, Sonia, additional, Schellongowski, Peter, additional, Sedlacek, Peter, additional, Sinko, Janos, additional, Slavin, Monica, additional, Ferreira, Isabella Sousa, additional, Styczynski, Jan, additional, Ward, Katherine, additional, and Witschi, Anne-Therese, additional

Published
2018
Full Text
View/download PDF

30. Antimicrobial resistance of nosocomial Enterococcus spp. isolated from blood culture in patients with hematological malignancies

Author

Klyasova, Galina A., primary, Fyodorova, Anastasiya V., additional, Frolova, I.N., additional, Khrulnova, Svetlana A., additional, Vetokhina, A.V., additional, Kaporskaya, T.S., additional, Skorobogatova, E.V., additional, Molchanova, I.V., additional, Pospelova, T.I., additional, Krainova, L.E., additional, Shushurina, S.E., additional, Khoreva, O.E., additional, Zvyozdkina, N.N., additional, and Kutsevalova, O.Yu., additional

Published
2018
Full Text
View/download PDF

31. Aetiology of hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation

Author

Vasilieva, Vera A., primary, Parovichnikova, E.N., additional, Drokov, M.Yu., additional, Kuzmina, L.A., additional, Klyasova, Galina A., additional, Tikhomirov, D.S., additional, Tupoleva, T.A., additional, Koroleva, O.M., additional, Dubnyak, D.S., additional, Mikhaltsova, E.D., additional, Popova, N.N., additional, Konova, Z.V., additional, and Savchenko, V.G., additional

Published
2018
Full Text
View/download PDF

33. Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients:Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group

Author

Averbuch, Diana, Tridello, Gloria, Hoek, Jennifer, Mikulska, Malgorzata, Akan, Hamdi, Yanez San Segundo, Lucrecia, Pabst, Thomas, Özçelik, Tülay, Klyasova, Galina, Donnini, Irene, Wu, Depei, Gülbas, Zafer, Zuckerman, Tsila, Botelho de Sousa, Aida, Beguin, Yves, Xhaard, Aliénor, Bachy, Emmanuel, Ljungman, Per, de la Camara, Rafael, Rascon, Jelena, Ruiz Camps, Isabel, Vitek, Antonin, Patriarca, Francesca, Cudillo, Laura, Vrhovac, Radovan, Shaw, Peter J, Wolfs, Tom, O'Brien, Tracey, Avni, Batia, Silling, Gerda, Al Sabty, Firas, Graphakos, Stelios, Sankelo, Marja, Sengeloev, Henrik, Pillai, Srinivas, Matthes, Susanne, Melanthiou, Frederiki, Iacobelli, Simona, Styczynski, Jan, Engelhard, Dan, Cesaro, Simone, Averbuch, Diana, Tridello, Gloria, Hoek, Jennifer, Mikulska, Malgorzata, Akan, Hamdi, Yanez San Segundo, Lucrecia, Pabst, Thomas, Özçelik, Tülay, Klyasova, Galina, Donnini, Irene, Wu, Depei, Gülbas, Zafer, Zuckerman, Tsila, Botelho de Sousa, Aida, Beguin, Yves, Xhaard, Aliénor, Bachy, Emmanuel, Ljungman, Per, de la Camara, Rafael, Rascon, Jelena, Ruiz Camps, Isabel, Vitek, Antonin, Patriarca, Francesca, Cudillo, Laura, Vrhovac, Radovan, Shaw, Peter J, Wolfs, Tom, O'Brien, Tracey, Avni, Batia, Silling, Gerda, Al Sabty, Firas, Graphakos, Stelios, Sankelo, Marja, Sengeloev, Henrik, Pillai, Srinivas, Matthes, Susanne, Melanthiou, Frederiki, Iacobelli, Simona, Styczynski, Jan, Engelhard, Dan, and Cesaro, Simone

Abstract

Background: This intercontinental study aimed to study gram-negative rod (GNR) resistance in hematopoietic stem cell transplantation (HSCT).Methods: GNR bacteremias occurring during 6 months post-HSCT (February 2014-May 2015) were prospectively collected, and analyzed for rates and risk factors for resistance to fluoroquinolones, noncarbapenem anti-Pseudomonas β-lactams (noncarbapenems), carbapenems, and multidrug resistance.Results: Sixty-five HSCT centers from 25 countries in Europe, Australia, and Asia reported data on 655 GNR episodes and 704 pathogens in 591 patients (Enterobacteriaceae, 73%; nonfermentative rods, 24%; and 3% others). Half of GNRs were fluoroquinolone and noncarbapenem resistant; 18.5% carbapenem resistant; 35.2% multidrug resistant. The total resistance rates were higher in allogeneic HSCT (allo-HSCT) vs autologous HSCT (auto-HSCT) patients (P < .001) but similar in community-acquired infections. Noncarbapenem resistance and multidrug resistance were higher in auto-HSCT patients in centers providing vs not providing fluoroquinolone prophylaxis (P < .01). Resistance rates were higher in southeast vs northwest Europe and similar in children and adults, excluding higher fluoroquinolone- and β-lactam/β-lactamase inhibitor resistance rates in allo-HSCT adults. Non-Klebsiella Enterobacteriaceae were rarely carbapenem resistant. Multivariable analysis revealed resistance risk factors in allo-HSCT patients: fluoroquinolone resistance: adult, prolonged neutropenia, breakthrough on fluoroquinolones; noncarbapenem resistance: hospital-acquired infection, breakthrough on noncarbapenems or other antibiotics (excluding fluoroquinolones, noncarbapenems, carbapenems), donor type; carbapenem resistance: breakthrough on carbapenem, longer hospitalization, intensive care unit, previous other antibiotic therapy; multidrug resistance: longer hospitalization, breakthrough on β-lactam/β-lactamase inhibitors, and carbapenems. Inappropriate empi

Published
2017

34. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Author

Maertens, Johan, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Alanio, Alexandre, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stã©phane, Cordonnier, Catherine, Agrawal, Samir, Kibbler, Christopher, Pagliuca, SIMONE ANTONIO, Ward, Katherine, Akova, Murat, Herbrecht, Raoul, Mallet, Vincent, Ribaud, Patricia, Aljurf, Mahmoud, Averbuch, Dina, Engelhard, Dan, Berg, Thomas, Cornely, Oliver, Penack, Olaf, van Boemmel, Florian, von Lilienfeld-Toal, Marie, Blennow, Ola, Ljungman, Per, Bruggemann, Roger, Donnelly, Peter, Kullberg, Bart-Jan, Melchers, Willem, Calandra, Thierry, Hirsch, Hans, Marchetti, Oscar, Orasch, Christina, Tissot, Frederic, Castagnola, Elio, Girmenia, Corrado, Mikulska, Malgorzata, Pagano, Livio, Viscoli, Claudio, De La Camara, Rafael, Duarte, Rafael, Munoz, Patricia, Drgona, Lubos, Hargreaves, Ruth, Hubacek, Petr, Kouba, Michal, Racil, Zdenek, Klyasova, Galina, Pettrikos, George, Roilides, Emmanuel, Skiada, Anna, Rizzi-Puechal, Valã©rie, Sinko, Janos, Slavin, Monica, Styczynski, Jan, Tweddle, Lorraine, Wood, Craig, Department of Hematology, University Hospital Gasthuisberg, G.B. Rossi Hospital, Verona University, Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Radboud university [Nijmegen], Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Lausanne University Hospital, Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire (CNRMA), Institut Pasteur [Paris], Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), The ECIL-5 meeting was supported by unrestricted educational grants from Astellas Pharma, Gilead Sciences, Merck, and Pfizer., University Hospital Gasthuisberg [Leuven], Università degli studi di Verona = University of Verona (UNIVR), Radboud University [Nijmegen], Julius-Maximilians-Universität Würzburg (JMU), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), and Institut Pasteur [Paris] (IP)

Subjects
0301 basic medicine, Microbiology (medical), Antifungal Agents, [SDV]Life Sciences [q-bio], 030106 microbiology, Pneumocitis jirovecii, Chemoprevention, Trimethoprim, Immunocompromised Host, 03 medical and health sciences, 0302 clinical medicine, Trimethoprim, Sulfamethoxazole Drug Combination, Humans, Pharmacology (medical), Pharmacology, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], Sulfamethoxazole Drug Combination, Pneumocystis, Hematologic Neoplasms, Pneumonia, Pneumocystis, Stem Cell Transplantation, Transplant Recipients, Infectious Diseases, immunocomrpomised host, pneumonia, Pneumocitis jirovecii, Pneumonia, 3. Good health, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], 030220 oncology & carcinogenesis, immunocomrpomised host, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Contains fulltext : 172373.pdf (Publisher’s version ) (Closed access) The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults ( A-II: ) and children ( A-I: ) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen ( B-II: ). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.

Published
2016

35. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Author

Alanio, Alexandre, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg Larsen, Jannik, Matos, Olga, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Cordonnier, Catherine, Maertens, Johan, Bretagne, Stã©phane, Agrawal, Samir, Kibbler, Christopher, Pagliuca, Antonio, Ward, Katherine, Akova, Murat, Herbrecht, Raoul, Mallet, Vincent, Ribaud, Patricia, Aljurf, Mahmoud, Averbuch, Dina, Engelhard, Dan, Berg, Thomas, Cornely, Oliver, Penack, Olaf, van Boemmel, Florian, von Lilienfeld Toal, Marie, Blennow, Ola, Ljungman, Per, Bruggemann, Roger, Donnelly, Peter, Kullberg, Bart Jan, Melchers, Willem, Calandra, Thierry, Hirsch, Hans, Marchetti, Oscar, Orasch, Christina, Tissot, Frederic, Castagnola, Elio, Girmenia, Corrado, Mikulska, MALGORZATA KAROLINA, Pagano, Livio, Viscoli, Claudio, De La Camara, Rafael, Duarte, Rafael, Munoz, Patricia, Drgona, Lubos, Hargreaves, Ruth, Hubacek, Petr, Kouba, Michal, Racil, Zdenek, Klyasova, Galina, Pettrikos, George, Roilides, Emmanuel, Skiada, Anna, Rizzi Puechal, Valã©rie, Sinko, Janos, Slavin, Monica, Styczynski, Jan, Tweddle, Lorraine, Wood, Craig, Centre National de Référence des Mycoses invasives et antifongiques - Mycologie moléculaire (CNRMA), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire, Université de Lausanne = University of Lausanne (UNIL), Université Catholique de Louvain = Catholic University of Louvain (UCL), Radboud University [Nijmegen], Rigshospitalet [Copenhagen], Copenhagen University Hospital, Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Università degli studi di Verona = University of Verona (UNIVR), Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Julius Maximilians University Wurzburg, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Department of Hematology, University Hospital Gasthuisberg [Leuven], The ECIL-5 meeting was supported by unrestricted educational grants from Astellas Pharma, Gilead Sciences, Merck, and Pfizer, Université de Lausanne (UNIL), Radboud university [Nijmegen], G.B. Rossi Hospital, Verona University, University Hospital Gasthuisberg, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), and Julius-Maximilians-Universität Würzburg (JMU)

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, [SDV]Life Sciences [q-bio], 030106 microbiology, Dapsone, Pneumocystis carinii, 03 medical and health sciences, Immunocompromised Host, 0302 clinical medicine, Diagnostic Tests, Internal medicine, medicine, Pneumocistis jirovecii, Humans, Routine, Pharmacology (medical), 030212 general & internal medicine, Intensive care medicine, Pharmacology, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], business.industry, Diagnostic Tests, Routine, Pneumocystis, Pneumonia, Pneumocystis, Pneumonia, medicine.disease, Trimethoprim, Transplant Recipients, 3. Good health, Fludarabine, Regimen, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Infectious Diseases, Hematologic Neoplasms, Alemtuzumab, Rituximab, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Pentamidine, medicine.drug, immunocompromised host, pneumonia, Pneumocistis jirovecii, Stem Cell Transplantation
Abstract

Item does not contain fulltext The Fifth European Conference on Infections in Leukaemia (ECIL-5) convened a meeting to establish evidence-based recommendations for using tests to diagnose Pneumocystis jirovecii pneumonia (PCP) in adult patients with haematological malignancies. Immunofluorescence assays are recommended as the most sensitive microscopic method (recommendation A-II: ). Real-time PCR is recommended for the routine diagnosis of PCP ( A-II: ). Bronchoalveolar lavage (BAL) fluid is recommended as the best specimen as it yields good negative predictive value ( A-II: ). Non-invasive specimens can be suitable alternatives ( B-II: ), acknowledging that PCP cannot be ruled out in case of a negative PCR result ( A-II: ). Detecting beta-d-glucan in serum can contribute to the diagnosis but not the follow-up of PCP ( A-II: ). A negative serum beta-d-glucan result can exclude PCP in a patient at risk ( A-II: ), whereas a positive test result may indicate other fungal infections. Genotyping using multilocus sequence markers can be used to investigate suspected outbreaks ( A-II: ). The routine detection of dihydropteroate synthase mutations in cases of treatment failure is not recommended ( B-II: ) since these mutations do not affect response to high-dose co-trimoxazole. The clinical utility of these diagnostic tests for the early management of PCP should be further assessed in prospective, randomized interventional studies.

Published
2016

36. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

Author

Marty, Francisco M., Ostrosky-Zeichner, Luis, Cornely, Oliver A., Mullane, Kathleen M., Perfect, John R., Thompson, George R., III, Alangaden, George J., Brown, Janice M., Fredricks, David N., Heinz, Werner J., Herbrecht, Raoul, Klimko, Nikolai, Klyasova, Galina, Maertens, Johan A., Melinkeri, Sameer R., Oren, Ilana, Pappas, Peter G., Racil, Zdenek, Rahav, Galia, Santos, Rodrigo, Schwartz, Stefan, Vehreschild, J. Janne, Young, Jo-Anne H., Chetchotisakd, Ploenchan, Jaruratanasirikul, Sutep, Kanj, Souha S., Engelhardt, Marc, Kaufh, Achim, Ito, Masanori, Lee, Misun, Sasse, Carolyn, Maher, Rochelle M., Zeiher, Bernhardt, Vehreschild, Maria J. G. T., Marty, Francisco M., Ostrosky-Zeichner, Luis, Cornely, Oliver A., Mullane, Kathleen M., Perfect, John R., Thompson, George R., III, Alangaden, George J., Brown, Janice M., Fredricks, David N., Heinz, Werner J., Herbrecht, Raoul, Klimko, Nikolai, Klyasova, Galina, Maertens, Johan A., Melinkeri, Sameer R., Oren, Ilana, Pappas, Peter G., Racil, Zdenek, Rahav, Galia, Santos, Rodrigo, Schwartz, Stefan, Vehreschild, J. Janne, Young, Jo-Anne H., Chetchotisakd, Ploenchan, Jaruratanasirikul, Sutep, Kanj, Souha S., Engelhardt, Marc, Kaufh, Achim, Ito, Masanori, Lee, Misun, Sasse, Carolyn, Maher, Rochelle M., Zeiher, Bernhardt, and Vehreschild, Maria J. G. T.

Abstract

Background Mucormycosis is an uncommon invasive fungal disease with high mortality and few treatment options. Isavuconazole is a triazole active in vitro and in animal models against moulds of the order Mucorales. We assessed the efficacy and safety of isavuconazole for treatment of mucormycosis and compared its efficacy with amphotericin B in a matched case-control analysis. Methods In a single-arm open-label trial (VITAL study), adult patients (>= 18 years) with invasive fungal disease caused by rare fungi, including mucormycosis, were recruited from 34 centres worldwide. Patients were given isavuconazole 200 mg (as its intravenous or oral water-soluble prodrug, isavuconazonium sulfate) three times daily for six doses, followed by 200 mg/day until invasive fungal disease resolution, failure, or for 180 days or more. The primary endpoint was independent data review committee-determined overall response-ie, complete or partial response (treatment success) or stable or progressive disease (treatment failure)-according to prespecified criteria. Mucormycosis cases treated with isavuconazole as primary treatment were matched with controls from the FungiScope Registry, recruited from 17 centres worldwide, who received primary amphotericin B-based treatment, and were analysed for day-42 all-cause mortality. VITAL is registered with ClinicalTrials.gov, number NCT00634049. FungiScope is registered with ClinicalTrials. gov, number NCT01731353. Findings Within the VITAL study, from April 22, 2008, to June 21, 2013, 37 patients with mucormycosis received isavuconazole for a median of 84 days (IQR 19-179, range 2-882). By day 42, four patients (11%) had a partial response, 16 (43%) had stable invasive fungal disease, one (3%) had invasive fungal disease progression, three (8%) had missing assessments, and 13 (35%) had died. 35 patients (95%) had adverse events (28 [76%] serious). Day-42 crude all-cause mortality in seven (33%) of 21 primary-treatment isavuconazole cases was sim

Published
2016

40. Non-Intensive but Constant and Exhausting Action on the Leukemic Clone Is a Reasonable and Effective Treatment Approach in Adult Acute Lymphoblastic Leukemia: Results of the Russian Acute Lymphoblastic Leukemia (RALL) Study Group

Author

Parovichnikova, Elena N., primary, Troitskaya, Vera, additional, Sokolov, Andrey N, additional, Klyasova, Galina, additional, Kuzmina, Larisa A, additional, Kravchenko, Sergey K., additional, Gribanova, Elena O., additional, Bondarenko, Sergey N, additional, Baranova, Olga Yu, additional, Kaporskaya, Tatiana, additional, Ryltzova, T, additional, Zagoskina, Tamara Pavlovna, additional, Zinina, E, additional, Samoilova, Olga, additional, Nizamutdinova, Alfiya, additional, Klimovich, A, additional, Karyakina, E, additional, Eluferieva, A, additional, Gavrilova, L, additional, Konstantinova, T, additional, Vopilina, N, additional, Lapin, Valeri, additional, Pristupa, Alexander, additional, Tikunova, T, additional, Akhmerzaeva, Zalina, additional, Obukhova, Tatiana, additional, Rusinov, Mikhail, additional, Kulikov, Sergey M., additional, and Savchenko, Valeri G, additional

Published
2014
Full Text
View/download PDF

41. Conventional 7+3 Consolidation Is Equal in Long-Term Outcome to High Dose ARA-C in Case of the High Total Doses of Different Anthracyclines/Anthracenedione in Induction/Consolidation - the Interim Results of Russian Randomized Multicenter AML-10 Trial

Author

Savchenko, Valeri G, primary, Parovichnikova, Elena N., additional, Sokolov, Andrey N, additional, Troitskaya, Vera V, additional, Kuzmina, Larisa A, additional, Klyasova, Galina, additional, Galstyan, Gennadyi, additional, Gribanova, Elena O., additional, Kravchenko, Sergey K., additional, Bondarenko, Sergey N, additional, Zagoskina, Tamara Pavlovna, additional, Gavrilova, Lyubov, additional, Konstantinova, Tatyana, additional, Kaporskaya, Tatyana, additional, Samoilova, Olga, additional, Pristupa, Alexander, additional, Anchukova, L, additional, Zinina, E, additional, Moskov, V, additional, Karyakina, E, additional, Nizamutdinova, Alfiya, additional, Klimovich, A, additional, Lapin, Valery, additional, Paramonova, E, additional, Obukhova, Tatiana, additional, and Kulikov, Sergey, additional

Published
2014
Full Text
View/download PDF

42. Treatment of Diffuse Large B-Cell Lymphomas

Author

Magomedova, Aminat U, primary, Kravchenko, Sergey K, additional, Kremenetskaya, Alexandra, additional, Zvonkov, Evgenyi, additional, Baryakh, Elena, additional, Mangasarova, Yana, additional, Kaplanskaya, Irina, additional, Samojlova, Rima, additional, Vorobjev, Ivan A, additional, Obuchova, Tatjana, additional, Karagjuljan, Suren, additional, Klyasova, Galina, additional, Shulutko, Elena, additional, Galstyan, Gennadii, additional, Marjin, Dmitrii, additional, Gabeeva, Nelya, additional, and Vorobjev, Andrey, additional

Published
2011
Full Text
View/download PDF

43. Pre-engraftment and post-engraftment Gram=negative rods bacteremia in HSCT patients: Risk factors and association with mortality

Author

Averbuch, Diana, Tridello, Gloria, Hoek, Jennifer, Mikulska, Malgorzata, Pabst, Thomas, Yanez San Segundo, Lucrecia, Akan, Hamdi, Ozcelik, Tulay, Donnini, Irene, Klyasova, Galina, Sousa, Aida Botelho, Zuckerman, Tsila, Wu, Depei, Tecchio, Cristina, La Camara, Rafael, Sahika Zeynep Aki, Ljungman, Per, Gulbas, Zafer, Nicolas, Emmanuelle, Calore, Elisabetta, Perruccio, Katia, Ram, Ron, Annaloro, Claudio, Martino, Rodrigo, Avni, Batia, Shaw, Peter, Gil, Lidia, Iacobelli, Simona, Styczynski, Jan, Engelhard, Dan, and Cesaro, Simone

44. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines

Author

Malgorzata Mikulska, Diana Averbuch, Frederic Tissot, Catherine Cordonnier, Murat Akova, Thierry Calandra, Marcello Ceppi, Paolo Bruzzi, Claudio Viscoli, Mahmoud Aljurf, Dina Averbuch, Rosemary Barnes, Ola Blennow, Pierre-Yves Bochud, Emilio Bouza, Stephane Bretagne, Roger Brüggemann, Jordi Carratala, Simone Cesaro, Oliver Cornely, Tina Dalianis, Rafael De La Camara, Peter Donnelly, Lubos Drgona, Rafael Duarte, Hermann Einsele, Dan Engelhard, Christopher Fox, Corrado Girmenia, Andreas Groll, Dag Heldal, Jannick Helweg Larsen, Raoul Herbrecht, Hans Hirsch, Elisabeth Johnson, Galina Klyasova, Minna Koskuenvo, Katrien Lagrou, Russel E. Lewis, Per Ljungman, Johan Maertens, Georg Maschmeyer, Marcio Nucci, Christophe Padoin, Livio Pagano, Antonio Pagliuca, Zdenek Racil, Patricia Ribaud, Christine Rinaldo, Valérie Rizzi Puechal, Emmanuel Roilides, Christine Robin, Montserrat Rovira, Markus Rupp, Sonia Sanchez, Peter Schellongowski, Peter Sedlacek, Janos Sinko, Monica Slavin, Isabella Sousa Ferreira, Jan Styczynski, Katherine Ward, Anne-Therese Witschi, Mikulska, Malgorzata, Averbuch, Diana, Tissot, Frederic, Cordonnier, Catherine, Akova, Murat, Calandra, Thierry, Ceppi, Marcello, Bruzzi, Paolo, Viscoli, Claudio, Aljurf, Mahmoud, Averbuch, Dina, Barnes, Rosemary, Blennow, Ola, Bochud, Pierre-Yve, Bouza, Emilio, Bretagne, Stephane, Brüggemann, Roger, Carratala, Jordi, Cesaro, Simone, Cornely, Oliver, Dalianis, Tina, De La Camara, Rafael, Donnelly, Peter, Drgona, Lubo, Duarte, Rafael, Einsele, Hermann, Engelhard, Dan, Fox, Christopher, Girmenia, Corrado, Groll, Andrea, Heldal, Dag, Larsen, Jannick Helweg, Herbrecht, Raoul, Hirsch, Han, Johnson, Elisabeth, Klyasova, Galina, Koskuenvo, Minna, Lagrou, Katrien, Lewis, Russel E., Ljungman, Per, Maertens, Johan, Maschmeyer, Georg, Nucci, Marcio, Padoin, Christophe, Pagano, Livio, Pagliuca, Antonio, Racil, Zdenek, Ribaud, Patricia, Rinaldo, Christine, Puechal, Valérie Rizzi, Roilides, Emmanuel, Robin, Christine, Rovira, Montserrat, Rupp, Marku, Sanchez, Sonia, Schellongowski, Peter, Sedlacek, Peter, Sinko, Jano, Slavin, Monica, Ferreira, Isabella Sousa, Styczynski, Jan, Ward, Katherine, and Witschi, Anne-Therese

Subjects
Neutropenic, Microbiology (medical), Ciprofloxacin, Febrile neutropenia, Infection, Levofloxacin, Multidrug resistance (MDR), Prevention, Quinolone, medicine.medical_specialty, Neutropenia, Guidelines as Topic, Infections, law.invention, 03 medical and health sciences, 0302 clinical medicine, Antibiotic resistance, Randomized controlled trial, law, Internal medicine, medicine, Humans, Ciprofloxacin, Febrile neutropenia, Infection, Levofloxacin, Multidrug resistance (MDR), Neutropenic, Prevention, Quinolone, Microbiology (medical), Infectious Diseases, 030212 general & internal medicine, Intensive care medicine, Infection Control, business.industry, Antibiotic Prophylaxis, medicine.disease, Anti-Bacterial Agents, Settore MED/15 - MALATTIE DEL SANGUE, Resistant bacteria, Critical appraisal, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Infectious Diseases, Hematologic Neoplasms, 030220 oncology & carcinogenesis, Haematological cancer, Observational study, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Fluoroquinolones
Abstract

Contains fulltext : 190513.pdf (Publisher’s version ) (Closed access) OBJECTIVES: Fluoroquinolone (FQ) prophylaxis was recommended in 2005 by European Conference on Infections in Leukemia (ECIL) for patients with prolonged neutropenia. In consideration of a worldwide increase in antibiotic resistance, the issue of FQ prophylaxis during neutropenia was re-evaluated. METHODS: Literature review of randomised controlled trials (RCT) and observational studies published in years 2006-2014 was performed. Their results were analysed in meta-analysis. Meta-regression model was applied to evaluate whether the rates of FQ resistance in community and hospital settings influenced the efficacy of FQ prophylaxis. The impact of FQ prophylaxis on colonisation and infection with resistant bacteria was reviewed. RESULTS: Two RCTs and 12 observational studies were identified. FQ prophylaxis did not have effect on mortality (pooled OR 1.01, 95%CI 0.73-1.41), but was associated with lower rate of bloodstream infections (BSI) (pooled OR 0.57, 95%CI 0.43-0.74) and episodes of fever during neutropenia (pooled OR 0.32, 95%CI 0.20-0.50). No effect of the background rate of FQ resistance on the efficacy of FQ prophylaxis was observed. In few studies, FQ prophylaxis resulted in an increased colonisation or infection with FQ- or multi-drug resistant strains. CONCLUSIONS: The possible benefits of FQ prophylaxis on BSI rate, but not on overall mortality, should be weighed against its impact in terms of toxicity and changes in local ecology in single centres.

Published
2018

45. Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope Ⓡ -Global Registry for Emerging Fungal Infections.

Author

Salmanton-García J, Koehler P, Kindo A, Falces-Romero I, García-Rodríguez J, Ráčil Z, Chen SC, Klimko N, Desoubeaux G, Thompson GR , III, Benítez-Peñuela MÁ, Rodríguez JY, Sheppard DC, Hoenigl M, Le Govic Y, Badali H, Baddley JW, Chander J, Ingram PR, Pakstis DL, Mellinghoff SC, Atıcı S, Cesaro S, Chakrabarti A, Dupont D, González GM, Hatvani L, Herbrecht R, Klyasova G, Lass-Flörl C, Mareș M, Mullane K, Vinh DC, Wisplinghoff H, Lackner M, Cornely OA, and Seidel D

Subjects
Antifungal Agents therapeutic use, Humans, Registries, Invasive Fungal Infections drug therapy, Invasive Fungal Infections epidemiology, Mycoses drug therapy, Mycoses epidemiology
Abstract

Objectives: Emerging invasive fungal infections (IFI) have become a notable challenge. Apart from the more frequently described fusariosis, lomentosporiosis, mucormycosis, scedosporiosis, and certain dematiaceae or yeasts, little is known about extremely rare IFI., Methods: Extremely rare IFI collected in the FungiScope Ⓡ registry were grouped as Dematiaceae, Hypocreales, Saccharomycetales, Eurotiales, Dermatomycetes, Agaricales, and Mucorales., Results: Between 2003 and June 2019, 186 extremely rare IFI were documented in FungiScope Ⓡ . Dematiaceae (35.5%), Hypocreales (23.1%), Mucorales (11.8%), and Saccharomycetales (11.3%) caused most IFI. Most patients had an underlying malignancy (38.7%) with acute leukemia accounting for 50% of cancers. Dissemination was observed in 26.9% of the patients. Complete or partial clinical response rate was 68.3%, being highest in Eurotiales (82.4%) and in Agaricales (80.0%). Overall mortality rate was 29.3%, ranging from 11.8% in Eurotiales to 50.0% in Mucorales., Conclusions: Physicians are confronted with a complex variety of fungal pathogens, for which treatment recommendations are lacking and successful outcome might be incidental. Through an international consortium of physicians and scientists, these cases of extremely rare IFI can be collected to further investigate their epidemiology and eventually identify effective treatment regimens., Competing Interests: Declaration of Competing Interest PK reports personal fees from Astellas Pharma GmbH, Gilead Sciences GmbH, Akademie für Infektionsmedizin e.V., MSD Sharp & Dohme GmbH, and University Hospital, LMU Munich; non-financial support from Miltenyi Biotec GmbH; and other support from Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany, outside the submitted work. SCAC reports grants from MSD Australia, outside the submitted work. NK reports personal fees from Astellas, Gilead, MSD, and Pfizer, outside the submitted work. DCS reports grants from Merck and personal fees from Merck, Astellas, and AVIR, outside the submitted work. MH reports grants from Gilead, outside the submitted work. SCM reports personal fees from Octapharma, outside the submitted work. RH reports grants from Gilead, Novartis, and Pfizer and personal fees from Astellas, Basilea, Gilead, MSD, Novartis, and Pfizer, outside the submitted work. GK reports personal fees from Astellas Pharma, Gilead Sciences, Merck Sharp and Dohme, Pfizer, and Sandoz outside the submitted work. CLF reports grants from Astellas Pharma and Gilead Sciences; personal fees from Angelini, Basilea, Biomerieux, Gilead Sciences, and Merck Sharp and Dohme; and other support from Astellas Pharma, Basilea, Biomerieux, Gilead Sciences, and Merck Sharp and Dohme, outside the submitted work. KM reports grants as a clinical trial investigator from Gilead Sciences, Inc., clinical research grants from Ansun, Astellas, Merck, Rebiotix, Scynexis, and Shire; and consultant fees/honoraria from Chimerix, GlaxoSmithKline, Merck, and Scynexis outside the submitted work. DCV reports support from Avir Pharma, Cidara Therapeutics, CSL Behring, and Fonds de la Recherche en Santé du Quebec, during the conduct of the study (salary support), outside the submitted work. OAC reports grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Medicines Company, MedPace, Melinta Therapeutics, Merck/MSD, Pfizer, and Scynexis and personal fees from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, F2G, Entasis, Gilead, Grupo Biotoscana, Matinas, MedPace, Menarini Ricerche, Merck/MSD, Nabriva Therapeutics Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Roche Diagnostics, Scynexis, Seres Therapeutics, and Tetraphase outside the submitted work. Other authors: none, (Copyright © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.)

Published
2020
Full Text
View/download PDF

46. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Author

Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, Engelhard D, and Akova M

Subjects
Anti-Bacterial Agents pharmacology, Drug Resistance, Bacterial drug effects, Europe epidemiology, Fever epidemiology, Fever microbiology, Humans, Leukemia epidemiology, Leukemia microbiology, Neutropenia epidemiology, Neutropenia microbiology, Anti-Bacterial Agents therapeutic use, Drug Resistance, Bacterial physiology, Fever drug therapy, Leukemia drug therapy, Neutropenia drug therapy, Practice Guidelines as Topic standards
Abstract

Owing to increasing resistance and the limited arsenal of new antibiotics, especially against Gram-negative pathogens, carefully designed antibiotic regimens are obligatory for febrile neutropenic patients, along with effective infection control. The Expert Group of the 4(th) European Conference on Infections in Leukemia has developed guidelines for initial empirical therapy in febrile neutropenic patients, based on: i) the local resistance epidemiology; and ii) the patient's risk factors for resistant bacteria and for a complicated clinical course. An 'escalation' approach, avoiding empirical carbapenems and combinations, should be employed in patients without particular risk factors. A 'de-escalation' approach, with initial broad-spectrum antibiotics or combinations, should be used only in those patients with: i) known prior colonization or infection with resistant pathogens; or ii) complicated presentation; or iii) in centers where resistant pathogens are prevalent at the onset of febrile neutropenia. In the latter case, infection control and antibiotic stewardship also need urgent review. Modification of the initial regimen at 72-96 h should be based on the patient's clinical course and the microbiological results. Discontinuation of antibiotics after 72 h or later should be considered in neutropenic patients with fever of unknown origin who are hemodynamically stable since presentation and afebrile for at least 48 h, irrespective of neutrophil count and expected duration of neutropenia. This strategy aims to minimize the collateral damage associated with antibiotic overuse, and the further selection of resistance.

Published
2013
Full Text
View/download PDF

47. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Author

Averbuch D, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, Engelhard D, and Akova M

Subjects
Drug Resistance, Multiple, Bacterial physiology, Europe epidemiology, Gram-Negative Bacterial Infections drug therapy, Gram-Negative Bacterial Infections microbiology, Gram-Positive Bacterial Infections drug therapy, Gram-Positive Bacterial Infections microbiology, Humans, Leukemia epidemiology, Leukemia microbiology, Anti-Bacterial Agents administration & dosage, Drug Delivery Systems methods, Drug Resistance, Multiple, Bacterial drug effects, Hematopoietic Stem Cell Transplantation adverse effects, Leukemia drug therapy, Practice Guidelines as Topic standards
Abstract

The detection of multi-resistant bacterial pathogens, particularly those to carbapenemases, in leukemic and stem cell transplant patients forces the use of old or non-conventional agents as the only remaining treatment options. These include colistin/polymyxin B, tigecycline, fosfomycin and various anti-gram-positive agents. Data on the use of these agents in leukemic patients are scanty, with only linezolid subjected to formal trials. The Expert Group of the 4(th) European Conference on Infections in Leukemia has developed guidelines for their use in these patient populations. Targeted therapy should be based on (i) in vitro susceptibility data, (ii) knowledge of the best treatment option against the particular species or phenotype of bacteria, (iii) pharmacokinetic/pharmacodynamic data, and (iv) careful assessment of the risk-benefit balance. For infections due to resistant Gram-negative bacteria, these agents should be preferably used in combination with other agents that remain active in vitro, because of suboptimal efficacy (e.g., tigecycline) and the risk of emergent resistance (e.g., fosfomycin). The paucity of new antibacterial drugs in the near future should lead us to limit the use of these drugs to situations where no alternative exists.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results